ALXO
Alx Oncology HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$257.95M
P/E Ratio
—
EPS
$-1.90
Beta
0.50
52W High
$2.66
52W Low
$0.40
50-Day MA
$2.08
200-Day MA
$1.39
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Alx Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 107,000 |
| EBITDA | $-100.14M |
| Operating Margin | 0.00% |
| Return on Equity | -145.70% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.48 |
| Price-to-Book | 9.98 |
| Price-to-Sales (TTM) | 5085.96 |
| EV/Revenue | 4287.72 |
| EV/EBITDA | -2.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $131.61M |
| Float | $104.10M |
| % Insiders | 1.19% |
| % Institutions | 40.28% |
Analyst Ratings
Consensus ($4.60 target)
1
Strong Buy3
Buy1
HoldData last updated: 4/7/2026